Document Detail

Antibody-linked cytotoxic agents in the treatment of cancer: current status and future prospects.
MedLine Citation:
PMID:  80453     Owner:  NLM     Status:  MEDLINE    
Antibodies against tumor cell surface antigens have been used as selective carriers of anticancer drugs, which themselves lack selectivity. Although such antibodies have been demonstrated in tumor hosts, xenogeneic antitumor sera should provide larger yields of better-defined antitumor antibodies for therapeutic purposes. This review examined factors that influence the immune response to tumor-associated transplantation antigens (TATA) and the methods for rendering tumor cells more immunogenic. Consideration was also given to techniques for elimination of irrelevant immunoglobulin molecules. These could involve purification of both antitumor sera and TATA fractions for immunization, as well as tailoring of the immunization protocol. Various toxic agents that have been linked to antitumor globulins with retention of agent and antibody activity were tabulated: alkylating drugs, antibiotics, antimetabolites, cell surface agents, protein synthesis inhibitors, and unconventional anticancer agents that selectively convert nontoxic arsenicals or halides into cytocidal derivatives. The methods by which effective conjugates can be produced and their possible mode of action were described for the different types of agents. Several problems inherent in this modality of tumor therapy include: 1) the necessity of binding therapeutically effective amounts of antitumor agent, 2) ensuring of delivery of drug in active form to target sites, 3) avoidance of host reactions to foreign proteins, and 4) possible emergence of resistant tumor cell populations. Antibody-linked cytotoxic agents may find their greatest use in the eradication of small numbers of circulating tumor cells and micrometastases remaining after removal of primary tumors.
T Ghose; A H Blair
Related Documents :
15956983 - Coexpression of cd40l and cd70 by semiallogenic tumor cells induces anti-tumor immunity.
17986853 - Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy.
15304163 - Assessment of the depth of myometrial invasion in stage i endometrioid endometrial canc...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of the National Cancer Institute     Volume:  61     ISSN:  0027-8874     ISO Abbreviation:  J. Natl. Cancer Inst.     Publication Date:  1978 Sep 
Date Detail:
Created Date:  1978-11-18     Completed Date:  1978-11-18     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7503089     Medline TA:  J Natl Cancer Inst     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  657-76     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alkylating Agents / administration & dosage
Antibiotics, Antineoplastic / administration & dosage
Antibodies, Neoplasm / administration & dosage*
Antibody Specificity
Antigens, Neoplasm
Antimetabolites, Antineoplastic / administration & dosage
Antineoplastic Agents / administration & dosage*
Bacterial Toxins / administration & dosage
Drug Resistance
Histocompatibility Antigens
Neoplasms / immunology,  therapy*
Phospholipases / administration & dosage
Plant Proteins / administration & dosage
Reg. No./Substance:
0/Alkylating Agents; 0/Antibiotics, Antineoplastic; 0/Antibodies, Neoplasm; 0/Antigens, Neoplasm; 0/Antimetabolites, Antineoplastic; 0/Antineoplastic Agents; 0/Bacterial Toxins; 0/Epitopes; 0/Histocompatibility Antigens; 0/Plant Proteins; EC 3.1.-/Phospholipases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Underutilization and misuse of audiovisual modes of communication by senior faculty.
Next Document:  Immunologic methods for the identification of cell types. II. Expression of normal mouse mammary epi...